Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HBH1
UPID:
DEFM_HUMAN
Alternative names:
Polypeptide deformylase
Alternative UPACC:
Q9HBH1; Q8WUN6
Background:
Peptide deformylase, mitochondrial, also known as Polypeptide deformylase, plays a crucial role in protein synthesis. It specifically removes the formyl group from the N-terminal Met of newly synthesized proteins, a vital step in the maturation and functionality of proteins within the cell.
Therapeutic significance:
Understanding the role of Peptide deformylase, mitochondrial could open doors to potential therapeutic strategies. Its unique function in protein synthesis presents an intriguing target for drug discovery, aiming to modulate protein production in diseases.